{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Brain+Neoplasms%2C+Benign",
    "query": {
      "condition": "Brain Neoplasms, Benign"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Brain+Neoplasms%2C+Benign&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T00:11:25.445Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00214175",
      "title": "Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioma",
        "Brain Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2004-06",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-02-24",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00214175"
    },
    {
      "nct_id": "NCT01445691",
      "title": "More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Benign Neoplasms, Brain",
        "Brain Cancer",
        "Brain Neoplasms, Benign",
        "Brain Neoplasms, Malignant",
        "Brain Tumor, Primary",
        "Brain Tumor, Recurrent",
        "Brain Tumors",
        "Intracranial Neoplasms",
        "Neoplasms, Brain",
        "Neoplasms, Intracranial",
        "Primary Brain Neoplasms",
        "Primary Malignant Brain Neoplasms",
        "Primary Malignant Brain Tumors",
        "Gliomas",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "5-ALA (Gliolan)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Constantinos Hadjipanayis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-05-17",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445691"
    },
    {
      "nct_id": "NCT01151670",
      "title": "Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Neoplasms, Malignant",
        "Brain Neoplasms, Benign",
        "Malignant Meningioma",
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2010-08",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151670"
    },
    {
      "nct_id": "NCT00003590",
      "title": "S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Meningioma"
      ],
      "interventions": [
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 29,
      "start_date": "1998-11",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 133,
      "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 97 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003590"
    },
    {
      "nct_id": "NCT03286335",
      "title": "Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Proton Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2018-09-26",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286335"
    },
    {
      "nct_id": "NCT02225197",
      "title": "A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tumor, Benign, Optic Nerve"
      ],
      "interventions": [
        {
          "name": "CyberKnife Radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Community Cancer Center, Normal, Illinois",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2007-12",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2019-07-25",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 1,
      "location_summary": "Normal, Illinois",
      "locations": [
        {
          "city": "Normal",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02225197"
    },
    {
      "nct_id": "NCT04278118",
      "title": "Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Grade I Meningioma",
        "Grade II Meningioma",
        "Grade III Meningioma",
        "Intracranial Neoplasm",
        "Nerve Sheath Neoplasm",
        "Pituitary Gland Adenoma",
        "Schwannoma"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Photon Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Proton Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-02-18",
      "completion_date": "2031-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04278118"
    },
    {
      "nct_id": "NCT00592865",
      "title": "Risk Factors for Adult-Onset Brain Tumors",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Neoplasm, Primary",
        "Brain Neoplasms, Malignant",
        "Brain Neoplasms, Benign"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 850,
      "start_date": "2003-10",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00592865"
    },
    {
      "nct_id": "NCT06322342",
      "title": "Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System (CNS) Lesions",
        "Brain Metastases",
        "Brain Neoplasms",
        "Brain Neoplasms, Benign",
        "Brain Tumor, Primary",
        "Brain Tumor, Recurrent",
        "Brain Tumors",
        "Brain Cancer",
        "Brain Tumor",
        "Brain Neoplasm, Primary",
        "Multiple Sclerosis",
        "Multiple Sclerosis Brain Lesion",
        "Neurofibroma",
        "Acoustic Neuroma",
        "CNS Tumor",
        "CNS Lesion",
        "CNS Metastases",
        "CNS Cancer",
        "CNS Lymphoma",
        "Von Hippel Lindau",
        "Meningioma",
        "Glioma",
        "Schwannomas",
        "Neuroinflammation",
        "Neoplasia"
      ],
      "interventions": [
        {
          "name": "RVP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reveal Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-08-15",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06322342"
    },
    {
      "nct_id": "NCT00790400",
      "title": "Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex (TSC)",
        "Lymphangioleiomyomatosis (LAM)"
      ],
      "interventions": [
        {
          "name": "Everolimus (RAD001)",
          "type": "DRUG"
        },
        {
          "name": "Everolimus Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2009-04",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-17",
      "last_synced_at": "2026-05-22T00:11:25.445Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790400"
    }
  ]
}